Skip to main content
GeneDx Holdings Corp. (WGS)
NASDAQ: WGS · IEX Real-Time Price · USD
20.92
+3.85 (22.55%)
At close: May 1, 2024, 4:00 PM
20.50
-0.42 (-2.01%)
After-hours: May 1, 2024, 7:58 PM EDT

GeneDx Holdings Revenue

GeneDx Holdings had revenue of $221.85M in the twelve months ending March 31, 2024, down -0.91% year-over-year. Revenue in the quarter ending March 31, 2024 was $62.42M with 44.70% year-over-year growth. In the year 2023, GeneDx Holdings had annual revenue of $202.57M, a decrease of -13.69%.

Revenue (ttm)
$221.85M
Revenue Growth
-0.91%
P/S Ratio
2.46
Revenue / Employee
$221,849
Employees
1,000
Market Cap
545.04M USD

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023202.57M-32.13M-13.69%
Dec 31, 2022234.69M22.50M10.60%
Dec 31, 2021212.20M32.87M18.33%
Dec 31, 2020179.32M-16.85M-8.59%
Dec 31, 2019196.17M62.83M47.12%
Dec 31, 2018133.34M--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Community Health Systems 12.52B
Aveanna Healthcare Holdings 1.90B
Pacific Biosciences of California 200.52M
Fate Therapeutics 63.53M
Taysha Gene Therapies 15.45M
Fulcrum Therapeutics 2.81M
Revenue Rankings

WGS News

More News